HER-2 expression

P2, N=17, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026

Present findings are from a small sample cohort and need further validation from a larger cohort. The online version contains supplementary material available at 10.1007/s13193-025-02427-0.

Moreover, this "Breast HERV19" expression signature was associated with better prognosis in HR+HER2- eBC, in which its expression was also correlated with biomarkers of sensitivity to anti PD-1 immunotherapy, such as tumor-infiltrating lymphocytes (TILs), PD-L1, and estrogen receptor (ER) expression levels. In eBC, our "Breast HERV19" expression signature makes it possible to isolate a subgroup of HR+HER2- tumors presenting strong immunogenicity, better prognosis, and biological characteristics that suggest a possible benefit from immunotherapy.

Particular attention is given to HER2-directed antibody-drug conjugates, especially trastuzumab deruxtecan (T-DXd), which have emerged as an important recent therapeutic advance and have renewed interest in HER2 as an actionable target in selected patients with HER2-expressing cervical carcinoma. This review further highlights the need for biomarker-driven patient selection, standardized HER2 assessment, and rational integration of HER2-directed strategies into precision treatment for CC.

These underscore the relevance of age-related biological factors in shaping breast cancer characteristics. However, among Indonesian women over 45 years old, the proportion of high breast density remains remarkably high (65.6%), suggesting that factors beyond age-such as genetic, hormonal, or lifestyle influences-may contribute to the persistence of dense breast tissue in this population.

P1/2, N=90, Recruiting, Canwell Biotech Limited | Not yet recruiting --> Recruiting

Although HER2-targeted therapies, such as trastuzumab deruxtecan, have shown promising results in HER2-positive bladder cancer, optimal immunohistochemistry (IHC) scoring criteria for urothelial carcinoma remain unclear...Upper GI and breast scoring criteria yield divergent scores in a significant subset of urothelial carcinomas, potentially affecting eligibility for targeted therapy. Associations with histologic subtype and metastatic site support disease-specific diagnostic and therapeutic strategies.

P2, N=120, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.

We discuss key lncRNAs implicated in TNBC pathogenesis and their potential as diagnostic biomarkers, prognostic indicators and therapeutic targets. By elucidating the complex interplay between lncRNAs and oncogenic pathways, this review underscores the promise of lncRNA-based strategies in improving TNBC management and patient outcomes.

P1/2, N=186, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Apr 2027

Conversely, the acquisition of HER2 positivity was significantly associated with high-grade (G3) tumors (ORadj = 5.50; 95% CI: 2.12-14.3; p 10% (ORadj = 8.61; 95% CI: 1.09-68.1; p = 0.041). HER2 status conversion affects about one-third of BCs after NAT, most commonly as downregulation, supporting HER2 reassessment in residual disease to guide post-NAT treatment decisions.

Al18F-NOTA-HER2-BCH retains developmental potential for detecting axillary lymph node metastasis in HER2-positive breast cancer, complementing 18F-FDG.